Literature DB >> 31611031

Characterization of biopsy proven non-alcoholic fatty liver disease in healthy non-obese and lean population of living liver donors: The impact of uric acid.

Ahad Eshraghian1, Saman Nikeghbalian2, Bita Geramizadeh2, Kourosh Kazemi2, Alireza Shamsaeefar2, Seyed Ali Malek-Hosseini2.   

Abstract

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is frequently seen among non-obese overweight individuals and lean subjects (those with normal body mass index). This study aimed to investigate prevalence and risk factors of biopsy proven NAFLD in a cluster of healthy non-obese and lean individuals. METHODS AND MATERIALS: In a retrospective study, adult (>18 years) apparently healthy individuals who had donated liver to pediatric patients between July 2012 and October 2018 were included. Non-obese and lean individuals were defined as BMI<30kg/m2 and BMI<25kg/m2, respectively.
RESULTS: Totally 310 patients were included. Seventy-six individuals (24.5%) had NAFL and 30 patients (9.67%) had non-alcoholic steatohepatitis (NASH) among non-obese population. In multivariate regression analysis, only higher BMI was marginally associated with NASH in non-obese compared to those without NASH (Odds ratio: 2.52, 95% CI: 0.097-6.54; P=0.05). Totally, 246 individuals were lean. 55 individuals (22.3%) had NAFL and 20 individuals (8.2%) had NASH in their liver biopsies. In univariate analysis, serum triglyceride, cholesterol, LDL, ALT, alkaline phosphatase and uric acid were associated with NAFL among lean individuals (P<0.05). In regression analysis, serum uric acid was associated with NAFL (Odds ratio: 1.70, 95% CI: 1.18-2.45; P=0.004) and NASH in lean individuals (Odds ratio: 1.98, 95% CI: 1.27-3.10; P=0.003).
CONCLUSION: NAFLD/NASH is prevalent even in a healthy lean population when evaluated by liver biopsy. Higher BMI and serum uric acid were two major risks of NAFLD/NASH in non-obese and lean individuals.
Copyright © 2019 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Lean individuals; Liver biopsy; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis

Year:  2019        PMID: 31611031     DOI: 10.1016/j.clinre.2019.09.002

Source DB:  PubMed          Journal:  Clin Res Hepatol Gastroenterol        ISSN: 2210-7401            Impact factor:   2.947


  6 in total

1.  Metabolic dysfunction is associated with steatosis but no other histologic features in nonalcoholic fatty liver disease.

Authors:  Yi-Ning Dai; Cheng-Fu Xu; Hong-Ying Pan; Hai-Jun Huang; Mei-Juan Chen; You-Ming Li; Chao-Hui Yu
Journal:  World J Clin Cases       Date:  2022-05-06       Impact factor: 1.534

2.  Conjunctional Relationship between Serum Uric Acid and Serum Nickel with Non-Alcoholic Fatty Liver Disease in Men: A Cross-Sectional Study.

Authors:  Chili Liu; Wannian Liu; Guofu Zhang; Yongbin Wang; Jing Jiang; Zhongzhi Yang; Weidong Wu
Journal:  Int J Environ Res Public Health       Date:  2022-05-25       Impact factor: 4.614

Review 3.  Determining the role for uric acid in non-alcoholic steatohepatitis development and the utility of urate metabolites in diagnosis: An opinion review.

Authors:  Paul Brennan; Kathleen Clare; Jacob George; John F Dillon
Journal:  World J Gastroenterol       Date:  2020-04-21       Impact factor: 5.742

Review 4.  Non-Alcoholic Steatohepatitis (NASH) and Organokines: What Is Now and What Will Be in the Future.

Authors:  João Paulo Margiotti Dos Santos; Mariana Canevari de Maio; Monike Alves Lemes; Lucas Fornari Laurindo; Jesselina Francisco Dos Santos Haber; Marcelo Dib Bechara; Pedro Sidnei do Prado; Eduardo Costa Rauen; Fernando Costa; Barbara Cristina de Abreu Pereira; Uri Adrian Prync Flato; Ricardo de Alvares Goulart; Eduardo Federighi Baisi Chagas; Sandra Maria Barbalho
Journal:  Int J Mol Sci       Date:  2022-01-02       Impact factor: 5.923

5.  Revealing the Mechanism of Huazhi Rougan Granule in the Treatment of Nonalcoholic Fatty Liver Through Intestinal Flora Based on 16S rRNA, Metagenomic Sequencing and Network Pharmacology.

Authors:  Yingying Liu; Yingying Tan; Jiaqi Huang; Chao Wu; Xiaotian Fan; Antony Stalin; Shan Lu; Haojia Wang; Jingyuan Zhang; Fanqin Zhang; Zhishan Wu; Bing Li; Zhihong Huang; Meilin Chen; Guoliang Cheng; Yanfang Mou; Jiarui Wu
Journal:  Front Pharmacol       Date:  2022-04-26       Impact factor: 5.988

6.  The Prevalence, Popular Trends, and Associated and Predictive Factors of Non-Obese Fatty Liver Disease.

Authors:  Jiang Deng; Yonghong Zhang; Limei Bu; Haitao Shi; Hailing Tang; Shenhao Wang; Qian Wang; Shuangsuo Dang; Ming Li; Zhiyi Han; Xiaolan Lu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-17       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.